We observed that the enhancing effect of GAS5 overexpression on IL‐10 is more significant in two cases of PBMCs derived from MG patients than in PBMCs derived from healthy controls, possibly due to the low basic IL‐10 level in PBMCs of MG patients. This evidence concerns the gene GAS5 and myasthenia gravis.